These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N; Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248 [TBL] [Abstract][Full Text] [Related]
47. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments. Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444 [TBL] [Abstract][Full Text] [Related]
48. Systemic juvenile idiopathic arthritis versus adult-onset Still´s disease: the pertinence of changing the current classification criteria. Silva JR; Brito I Acta Reumatol Port; 2020; 45(2):150-151. PubMed ID: 32895357 [TBL] [Abstract][Full Text] [Related]
49. JAK inhibitors in systemic juvenile idiopathic arthritis. He T; Xia Y; Luo Y; Yang J Front Pediatr; 2023; 11():1134312. PubMed ID: 37152309 [TBL] [Abstract][Full Text] [Related]
50. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience. Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940 [TBL] [Abstract][Full Text] [Related]
51. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725 [TBL] [Abstract][Full Text] [Related]
52. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates. Khawaja K; Al-Maini M Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684 [TBL] [Abstract][Full Text] [Related]
53. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528 [TBL] [Abstract][Full Text] [Related]
54. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Aygun D; Sahin S; Adrovic A; Barut K; Cokugras H; Camcıoglu Y; Kasapcopur O Clin Rheumatol; 2019 Apr; 38(4):1025-1030. PubMed ID: 30448935 [TBL] [Abstract][Full Text] [Related]
55. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329 [TBL] [Abstract][Full Text] [Related]
56. Joint lavage for treating recurrent knee involvement in patients with juvenile idiopathic arthritis. Sornay-Soares C; Job-Deslandre C; Kahan A Joint Bone Spine; 2004 Jul; 71(4):296-9. PubMed ID: 15288854 [TBL] [Abstract][Full Text] [Related]
57. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180 [TBL] [Abstract][Full Text] [Related]
58. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397 [TBL] [Abstract][Full Text] [Related]
59. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108 [TBL] [Abstract][Full Text] [Related]